Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer
- 27 November 2009
- journal article
- phase ii-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (2) , 360-365
Abstract
We performed a single-institution phase II study to evaluate the efficacy and toxicities of vinorelbine monotherapy in patients previously treated with anthracyclines and taxanes. Vinorelbine was administered at a dose level of 25 mg/m2 intravenously on days 1, 8, 15 and 22, every four weeks, and responses were assessed after every two cycles of treatment. All of the patients had previously been treated with anthracyclines and taxanes. A total of 26 patients were enrolled in this study between April 2004 and August 2009. The median age of the patients was 47 years (range, 37 to 71 years), and 80.8% had an Eastern Cooperative Oncology Group performance status of 0 or 1. Out of 24 evaluable patients, five partial responses were observed, giving an overall response rate of 20.8%, with a median response duration of 2.8 months. The median time to progression was 3.7 months (range, 0.5 to 22.6 months), and median overall survival duration was 10.4 months (range, 1.3 to 57.6 months). The major toxicities observed were neutropenia, anemia and peripheral neuropathy. Grade 3 or 4 hematologic toxicities included neutropenia in 18 patients (69.2%) and anemia in four patients (15.3%). Grade 1 or 2 peripheral neuropathy was observed in 11 patients (42.3%), however there were no cases of grade 3 or 4 peripheral neuropathy. The results of this study indicate that vinorelbine monotherapy was feasible regimen with manageable toxicities in patients with metastatic breast cancer who were previously exposed to anthracyclines and taxanes.Keywords
This publication has 17 references indexed in Scilit:
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI: Journal of the National Cancer Institute, 2009
- National Cancer Incidence for the Year 2002 in KoreaCancer Research and Treatment, 2007
- Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and TaxanesJapanese Journal of Clinical Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.European Journal of Cancer, 2000
- Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or olderAnnals of Oncology, 1999
- Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.Journal of Clinical Oncology, 1997
- Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II studyCancer Chemotherapy and Pharmacology, 1996
- Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II studyBreast Cancer Research and Treatment, 1996
- Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer ChemotherapyAmerican Journal of Clinical Oncology, 1995